{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:21:35Z","timestamp":1760188895635,"version":"3.33.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.1007\/s11882-003-0072-z","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T16:24:51Z","timestamp":1180974291000},"page":"389-395","source":"Crossref","is-referenced-by-count":10,"title":["Secondary immune deficiencies associated with biological therapeutics"],"prefix":"10.1007","volume":"3","author":[{"given":"Susan J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parekha","family":"Yedla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"72_CR1","first-page":"585","volume":"16","author":"HA Fuchs","year":"1989","unstructured":"Fuchs HA, Kaye JJ, Callahan LF, et al.: Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989, 16:585\u2013591.","journal-title":"J Rheumatol"},{"key":"72_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev.med.51.1.207","volume":"51","author":"RN Maini","year":"2000","unstructured":"Maini RN, Taylor PC: Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000, 51:207\u2013229. This article provides an overview on the rationale of anti-cytokine therapies in RA. It further reviews both the clinical efficacy and safety data from recent clinical trials.","journal-title":"Annu Rev Med"},{"key":"72_CR3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EHS Choy","year":"2001","unstructured":"Choy EHS, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907\u2013916.","journal-title":"N Engl J Med"},{"key":"72_CR4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1476-5381.1992.tb14503.x","volume":"107","author":"FQ Cunha","year":"1992","unstructured":"Cunha FQ, Poole S, Lorenzetti BB, et al.: The pivotal role of tumor necrosis alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 1992, 107:660\u2013669.","journal-title":"Br J Pharmacol"},{"key":"72_CR5","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1084\/jem.163.6.1433","volume":"163","author":"C Dinarello","year":"1986","unstructured":"Dinarello C, Cannon J, Wolff S: Tumor necrosis factor is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 1986, 163:1433\u20131450.","journal-title":"J Exp Med"},{"key":"72_CR6","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.162.6.2163","volume":"162","author":"JM Dayer","year":"1985","unstructured":"Dayer JM, Beutler B, Cerami A, et al.: Cachectin\/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985, 162:2163\u20132168.","journal-title":"J Exp Med"},{"key":"72_CR7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/322547a0","volume":"322","author":"J Saklatvala","year":"1986","unstructured":"Saklatvala J: Tumor necrosis factor-_ stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986, 322:547\u2013549.","journal-title":"Nature"},{"key":"72_CR8","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.10294","volume":"46","author":"LW Moreland","year":"2002","unstructured":"Moreland LW, Alten R, Van den Bosch F, et al.: Costimulatory blockade in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:1470\u20131479.","journal-title":"Arthritis Rheum"},{"key":"72_CR9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","volume":"103","author":"JR Abrams","year":"1999","unstructured":"Abrams JR, Lebwohl MG, Guzzo CA, et al.: CTLA4 Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243\u20131252.","journal-title":"J Clin Invest"},{"key":"72_CR10","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/eji.1830261008","volume":"26","author":"LM Webb","year":"1996","unstructured":"Webb LM, Walmsley MJ, Feldmann M: Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 1996, 26:2320\u20132328.","journal-title":"Eur J Immunol"},{"key":"72_CR11","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","volume":"46","author":"Vita S De","year":"2002","unstructured":"De Vita S, Zaja F, Sacco S, et al.: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum 2002, 46:2029\u20132933.","journal-title":"Arthritis Rheum"},{"key":"72_CR12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","volume":"61","author":"MJ Leandro","year":"2002","unstructured":"Leandro MJ, Edwards JC, Cambridge G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002, 61:883\u2013888.","journal-title":"Ann Rheum Dis"},{"key":"72_CR13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00002281-200205000-00002","volume":"14","author":"LG Criscione","year":"2002","unstructured":"Criscione LG, St Clair EW: Tumor necrosis factor-_ antagonists for the treatment of rheumatic diseases. Curr Opin Rheum 2002, 14:204\u2013211.","journal-title":"Curr Opin Rheum"},{"key":"72_CR14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/clim.2002.5191","volume":"103","author":"J Shanahan","year":"2002","unstructured":"Shanahan J, St Clair EW: Short analytical review, tumor necrosis factor blockade: a novel therapy for rheumatic disease. Clin Immunol 2002, 103:231\u2013242.","journal-title":"Clin Immunol"},{"issue":"Suppl","key":"72_CR15","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.60.90003.iii2","volume":"60","author":"DE Furst","year":"2001","unstructured":"Furst DE, Keystone EC, Breedveld FC, et al.: Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis 2001, 60(Suppl):iii2-iii5.","journal-title":"Ann Rheum Dis"},{"key":"72_CR16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, et al.: Adalimumab, a fully human anti-tumor necrosis factor _ monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 2003, 48:35\u201345.","journal-title":"Arthritis Rheum"},{"key":"72_CR17","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, et al.: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287\u20132293. This retrospective longitudinal cohort study of RA patients suggests that RA patients have a higher rate of infection compared with age-matched controls. This has important implications when assessing the safety profile of various therapeutic agents used for the treatment of RA.","journal-title":"Arthritis Rheum"},{"key":"72_CR18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","volume":"317","author":"E Baecklund","year":"1998","unstructured":"Baecklund E, Ekbom A, Sparen P, et al.: Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998, 317:180\u2013181.","journal-title":"BMJ"},{"key":"72_CR19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L","volume":"43","author":"PC Taylor","year":"2000","unstructured":"Taylor PC, Peters M, Paleolog EM, et al.: Reduction of chemokines levels and leukocyte traffic to joints by TNF-_ blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:38\u201347.","journal-title":"Arthritis Rheum"},{"key":"72_CR20","first-page":"232","volume":"30","author":"Broeder A Den","year":"2003","unstructured":"Den Broeder A, Wanten GJ, Oyen WJ, et al.: Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-_ monoclonal antibody in patients with rheumatoid arthritis. J Rheumatol 2003, 30:232\u2013237.","journal-title":"J Rheumatol"},{"key":"72_CR21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/art.1780390703","volume":"39","author":"EM Paleolog","year":"1996","unstructured":"Paleolog EM, Hunt M, Elliot MJ, et al.: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor-_ antibody in rheumatoid arthritis. Arthritis Rheum 1996, 39:1082\u20131091.","journal-title":"Arthritis Rheum"},{"key":"72_CR22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/art.1780390702","volume":"39","author":"PP Tak","year":"1996","unstructured":"Tak PP, Taylor PC, Breedveld FC, et al.: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor _ monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1077\u20131081.","journal-title":"Arthritis Rheum"},{"key":"72_CR23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","volume":"50","author":"Hove T Ten","year":"2002","unstructured":"Ten Hove T, Van Montfrans C, Peppelenbosch MP, et al.: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease. Gut 2002, 50:206\u2013211.","journal-title":"Gut"},{"key":"72_CR24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/cyto.1999.0552","volume":"12","author":"S Ohshima","year":"2000","unstructured":"Ohshima S, Mima T, Sasai M, et al.: Tumour necrosis factor _ (TNF-_) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-_ therapy for RA. Cytokine 2000, 12:281\u2013288.","journal-title":"Cytokine"},{"issue":"Suppl","key":"72_CR25","first-page":"S132","volume":"45","author":"A Kavanaugh","year":"2002","unstructured":"Kavanaugh A, Greenwald M, Zizic T, et al.: Treatment with adalimumab does not affect normal immune responsiveness. Arthritis Rheum 2002, 45(Suppl):S132.","journal-title":"Arthritis Rheum"},{"key":"72_CR26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/clim.2001.5183","volume":"103","author":"LW Moreland","year":"2002","unstructured":"Moreland LW, Bucy RP, Weinblatt ME, et al.: Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002, 103:13\u201321.","journal-title":"Clin Immunol"},{"key":"72_CR27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.60.2.133","volume":"60","author":"L Berg","year":"2001","unstructured":"Berg L, Lampa J, Rogberg S, et al.: Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF-_ receptors. Ann Rheum Dis 2001, 60:133\u2013139.","journal-title":"Ann Rheum Dis"},{"key":"72_CR28","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1084\/jem.185.9.1573","volume":"185","author":"AP Cope","year":"1997","unstructured":"Cope AP, Liblau RS, Yang XD, et al.: Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997, 185:1573\u20131584.","journal-title":"J Exp Med"},{"key":"72_CR29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/ard.61.8.723","volume":"61","author":"V Pittoni","year":"2002","unstructured":"Pittoni V, Bombardierei M, Spinelli FR, et al.: Anti-tumor necrosis factor-_ treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of IL-18 but not of IL-12 and IL-13. Ann Rheum Dis 2002, 61:723\u2013725.","journal-title":"Ann Rheum Dis"},{"key":"72_CR30","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon SK, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor _-neutralizing agent. N Engl J Med 2001, 345:1098\u20131104.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"72_CR31","first-page":"S78","volume":"44","author":"WJ Wallis","year":"2001","unstructured":"Wallis WJ, Burge DJ, Sabath D, et al.: Tuberculosis reports with etanercept therapy. Arthritis Rheum 2001, 44(Suppl):S78.","journal-title":"Arthritis Rheum"},{"issue":"Suppl28","key":"72_CR32","first-page":"S34","volume":"20","author":"JX Zou","year":"2002","unstructured":"Zou JX, Braun J, Sieper J: Immunological basis for the use of TNFa-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002, 20(Suppl28):S34-S37.","journal-title":"Clin Exp Rheumatol"},{"key":"72_CR33","unstructured":"Cush JJ, Kavanaugh A: ACR Hotline: FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis. http:\/\/www.rheumatology.org. Accessed May 1, 2003."},{"key":"72_CR34","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/ard.60.10.950","volume":"60","author":"AP Cairns","year":"2001","unstructured":"Cairns AP, Crockard AD, McConnell JR, et al.: Reduced expression of CD44 on monocytes and neutrophils in SLE: relations with apoptotic neutrophils and disease activity. Ann Rheum Dis 2001, 60:950\u2013955.","journal-title":"Ann Rheum Dis"},{"key":"72_CR35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/ard.61.11.1031","volume":"61","author":"AP Cairns","year":"2002","unstructured":"Cairns AP, Duncan MKJ, Hinder AE, et al.: New onset SLE in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002, 61:1031\u20131032.","journal-title":"Ann Rheum Dis"},{"key":"72_CR36","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"RN Maini","year":"1999","unstructured":"Maini RN, St Clair EW, Breedveld F, et al.: Infliximab (chimeric anti-tumor necrosis factor _ monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999, 354:1932\u20131939.","journal-title":"Lancet"},{"key":"72_CR37","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","volume":"43","author":"PJ Charles","year":"2000","unstructured":"Charles PJ, Smenk RJT, De Jong J, et al.: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor _: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000, 43:2383\u20132390.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 14","key":"72_CR38","first-page":"66","volume":"26","author":"AJ Grillo-Lopez","year":"1999","unstructured":"Grillo-Lopez AJ, White CA, Varns C, et al.: Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999, 26(Suppl 14):66\u201373.","journal-title":"Semin Oncol"},{"key":"72_CR39","first-page":"189","volume":"87","author":"F Zaja","year":"2002","unstructured":"Zaja F, Iacona I, Masolini P, et al.: B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002, 87:189\u2013195.","journal-title":"Haematologica"},{"issue":"suppl 14","key":"72_CR40","first-page":"74","volume":"26","author":"DG Maloney","year":"1999","unstructured":"Maloney DG: Preclinical and phase I and II trials of rituximab. Semin Oncol 1999, 26(suppl 14):74\u201378.","journal-title":"Semin Oncol"},{"issue":"Suppl 2","key":"72_CR41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","volume":"29","author":"DG Maloney","year":"2002","unstructured":"Maloney DG, Smith B, Rose A: Rituximab: mechanism of action and resistance. Semin Oncol 2002, 29(Suppl 2):2\u20139. This article provides a spectrum of proposed rituximab mechanisms of action, which are essential in understanding its role in the treatment of various autoimmune and neoplastic diseases.","journal-title":"Semin Oncol"},{"key":"72_CR42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/clim.2000.4980","volume":"98","author":"GV Gonzales-Stawinski","year":"2001","unstructured":"Gonzales-Stawinski GV, Yu PB, Love SD, et al.: Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 2001, 98:175\u2013179.","journal-title":"Clin Immunol"},{"key":"72_CR43","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","volume":"100","author":"LE Kolk Van der","year":"2002","unstructured":"Van der Kolk LE, Baars JW, Prins MH, et al.: Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002, 100:2257\u20132259.","journal-title":"Blood"},{"key":"72_CR44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.gene.6363655","volume":"1","author":"OP Kristiansen","year":"2000","unstructured":"Kristiansen OP, Larsen ZM, Pociet F: CTLA-4 in autoimmune disease: a general susceptibility gene to autoimmunity? Genes Immun 2000, 1:170\u2013184.","journal-title":"Genes Immun"},{"key":"72_CR45","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/eji.1830261008","volume":"26","author":"LMC Webb","year":"1996","unstructured":"Webb LMC, Walmsley MJ, Feldmann M: Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 1996, 26:2320\u20132328.","journal-title":"Eur J Immunol"},{"key":"72_CR46","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/art.10578","volume":"46","author":"G Nuki","year":"2002","unstructured":"Nuki G, Bresnihan B, Bear MB, et al.: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:2838\u20132846.","journal-title":"Arthritis Rheum"},{"issue":"Suppl2","key":"72_CR47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sarh.2001.23701","volume":"30","author":"B Bresnihan","year":"2001","unstructured":"Bresnihan B: The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2001, 30(Suppl2):17\u201320.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-003-0072-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-003-0072-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-003-0072-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T22:26:35Z","timestamp":1737066395000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-003-0072-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["72"],"URL":"https:\/\/doi.org\/10.1007\/s11882-003-0072-z","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"type":"print","value":"1529-7322"},{"type":"electronic","value":"1534-6315"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}